☆ 4.7 Meeting Abstract

Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: Clinical results from phase I trial

JOURNAL OF CLINICAL ONCOLOGY (2008)

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 26, Issue 15, Pages -

Publisher

AMER SOC CLINICAL ONCOLOGY

DOI: 10.1200/jco.2008.26.15_suppl.10503

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Oncology

Gastrointestinal Stromal Tumors: What Is the Best Sequence of TKIs?

Jordan Senchak, Katya Ahr, Margaret von Mehren

Summary: This review focuses on the management of GIST with KIT and PDGFRA mutations, providing recommendations for TKI therapy based on mutation status. Avapritinib is the preferred TKI for patients with PDGFRA D842V mutation. Biopsies and ctDNA testing play important roles in guiding treatment decisions.

CURRENT TREATMENT OPTIONS IN ONCOLOGY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Heat Shock Protein 90 (Hsp90) and Hsp70 as Potential Therapeutic Targets in Autoimmune Skin Diseases

Stefan Tukaj, Krzysztof Sitko

Summary: Over a hundred different autoimmune diseases have been described to date, affecting various organs including the skin. The loss of immune tolerance in autoimmune diseases leads to chronic inflammation and tissue damage. Current treatments focus on immunosuppression but may cause serious adverse effects. Heat shock proteins Hsp90 and Hsp70 have been identified as potential therapeutic targets for autoimmune skin diseases.

BIOMOLECULES (2022)

Add to Collection

Article Oncology

Combined BRAF, MEK, and heat-shock protein 90 (HSP90) inhibition in advanced BRAF V600-mutant melanoma

Zeynep Eroglu, Y. Ann Chen, Inna Smalley, Jiannong Li, Joseph K. Markowitz, Andrew S. Brohl, Leticia Tetteh, Hayley Taylor, Vernon K. Sondak, Nikhil I. Khushalani, Keiran S. M. Smalley

Summary: In this study, the efficacy and safety of vemurafenib and cobimetinib in combination with different doses of the HSP90 inhibitor XL888 for the treatment of advanced melanoma were explored. The study found that this combination therapy showed activity in some patients, but also had significant toxicity.

CANCER (2023)

Add to Collection

Article Pharmacology & Pharmacy

Virtual screening based identification of miltefosine and octenidine as inhibitors of heat shock protein 90

Lihong Li, Man Yang, Chenyao Li, Yajun Liu

Summary: HSP90 is a crucial molecular chaperone involved in cancer processes and is considered a promising target for anticancer drug development. Miltefosine and Octenidine were identified as new HSP90 inhibitors with strong and broad-spectrum anticancer activity, disrupting the chaperone function of HSP90.

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2021)

Add to Collection

Review Cell Biology

Targeting Heat-Shock Protein 90 in Cancer: An Update on Combination Therapy

Xiude Ren, Tao Li, Wei Zhang, Xuejun Yang

Summary: Heat-shock protein 90 (HSP90) is an important molecule chaperone associated with tumorigenesis and malignancy. It plays a role in the malignant behaviors of cancer cells, but currently there are no effective single-agent treatments. Combining HSP90 inhibitors with other anticancer therapies may be a better strategy.

CELLS (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Functional and Stress Response Analysis of Heat Shock Proteins 40 and 90 of Giant River Prawn (Macrobrachium rosenbergii) under Temperature and Pathogenic Bacterial Exposure Stimuli

Tanya Ju-Ngam, Nichanun McMillan, Mamoru Yoshimizu, Hisae Kasai, Ratree Wongpanya, Prapansak Srisapoome

Summary: This research conducted molecular characterization and biofunctional analyses of Hsp40 and Hsp90 genes in giant river prawns under various stress conditions. The highest similarity scores of these genes were found with crustaceans. Expression patterns of Mr-hsp40 and Mr-hsp90 were different under Aeromonas hydrophila challenge and heat-cold shock conditions, highlighting their significant roles in stress responses.

BIOMOLECULES (2021)

Add to Collection

Article Immunology

Heat shock protein 90 inhibitor RGRN-305 potently attenuates skin inflammation

Hakim Ben Abdallah, Sabine Seeler, Anne Bregnhoj, Gautam Ghatnekar, Lasse S. Kristensen, Lars Iversen, Claus Johansen

Summary: RGRN-305, an HSP90 inhibitor, exhibits anti-inflammatory effects by suppressing key proinflammatory cytokines and signaling pathways in TPA-induced skin inflammation. This study suggests that HSP90 inhibition may be a novel mechanism of action for treating immune-mediated skin diseases beyond psoriasis, and it may serve as a topical treatment option.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Review Immunology

Targeting heat shock proteins 90 and 70: A promising remedy for both autoimmune bullous diseases and COVID-19

Michael Kasperkiewicz, Stefan Tukaj

Summary: This mini review briefly summarizes the promising double-edged sword of targeting Hsp90/70 in the therapy of AIBDs and COVID-19.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Oncology

Novel peptide-based vaccine targeting heat shock protein 90 induces effective antitumor immunity in a HER2+breast cancer murine model

Jinho Kang, Hye-Jin Lee, Jimin Lee, Jinhwa Hong, Yeul Hong Kim, Mary L. Disis, Jeong-An Gim, Kyong Hwa Park

Summary: This study identified HSP90-derived MHC class II epitopes using in silico algorithms and validated their effectiveness using in vivo experiments. The HSP90 peptide vaccines showed potential for improving breast cancer treatment by activating T cells, increasing T-cell recruitment in the immune microenvironment, and rearranging TCRE3.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Cell Biology

The Heat Shock Protein 90 Inhibitor, AT13387, Protects the Alveolo-Capillary Barrier and Prevents HCl-Induced Chronic Lung Injury and Pulmonary Fibrosis

Ruben M. L. Colunga Biancatelli, Pavel Solopov, Christiana Dimitropoulou, Betsy Gregory, Tierney Day, John D. Catravas

Summary: The HSP90 inhibitor, AT13387, shows promising potential in preventing chronic lung injury induced by HCl and protecting the endothelial barrier. It reduces inflammation and fibrosis caused by HCl exposure and restores lung function.

CELLS (2022)

Add to Collection

Article Oncology

Sunitinib with concomitant radiation therapy in inoperable sarcomas: Final results from the dose escalation and expansion parts of a multicenter phase I study

Marie-Pierre Sunyach, Nicolas Penel, Laure Montane, Philippe A. Cassier, Abel Cordoba Largo, Paul Sargos, Ellen Blanc, David Perol, Jean-Yves Blay

Summary: This French study assessed the feasibility and safety of continuous administration of sunitinib with concomitant radiotherapy in inoperable non-GIST sarcomas patients. The combination treatment was found to be feasible and effective, but further investigations on combinations with more recent multikinase inhibitors and radiotherapy are needed.

RADIOTHERAPY AND ONCOLOGY (2022)

Add to Collection

Article Anesthesiology

Expression of ectopic heat shock protein 90 in male and female primary afferent nociceptors regulates inflammatory pain

Yaomin Wang, Scott A. Scarneo, Shin Hyung Kim, Xin Zhang, Jiegen Chen, Kelly W. Yang, Philip Hughes, Timothy Haystead, Andrea G. Nackley

Summary: Through a study on a mouse model, we found that the expression of eHsp90 on nociceptors increases during inflammation, and inhibiting eHsp90 can alleviate pain and inflammatory response. This finding provides a new approach for developing gender-tailored treatments for inflammatory pain.

PAIN (2022)

Add to Collection

Article Biochemistry & Molecular Biology

The Activity and Stability of p56Lck and TCR Signaling Do Not Depend on the Co-Chaperone Cdc37

Sarah Kowallik, Andreas Kritikos, Matthias Kaestle, Christoph Thurm, Burkhart Schraven, Luca Simeoni

Summary: Experimental data does not support the idea that Cdc37 regulates the activity/stability of Lck, as evidenced by unaffected Lck stability and TCR signaling in T cells with augmented or suppressed Cdc37 expression.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Oncology

Discovery of an orally active antitumor agent that induces apoptosis and suppresses EMT through heat shock protein 90 inhibition

Yuqiang Hu, Ming Hao, Chang Zhong, Jun An, Yongsheng Zhang, Zuobin Zhu, Bing Liu, Liangjun Cheng

Summary: HYQ97, a chalcone derivative, is a promising candidate for lung cancer treatment. It inhibits proliferation, degrades Hsp90, inhibits epithelial mesenchymal transition, induces apoptosis in lung cancer cell lines, and has significant inhibitory effects on tumor growth in vivo.

INVESTIGATIONAL NEW DRUGS (2021)

Add to Collection

Article Agriculture, Dairy & Animal Science

Evaluation of antioxidant property of heat shock protein 90 from duck muscle

Muhan Zhang, Daoying Wang, Xinglian Xu, Weimin Xu

Summary: The study found that Hsp90 could bind with phospholipids and oxidized phospholipids, preventing their further oxidation; Hsp90 exhibited scavenging activity on DPPH and ABTS radicals; Additionally, Hsp90 was shown to directly scavenge hydroxyl and PTIO radicals.

ANIMAL BIOSCIENCE (2021)

Add to Collection

Article Oncology

Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival

Vadim S. Koshkin, Vanessa Bolejack, Lawrence H. Schwartz, Richard L. Wahl, Rashmi Chugh, Denise K. Reinke, Binsheng Zhao, Joo H. O, Shreyaskumar R. Patel, Scott M. Schuetze, Laurence H. Baker

JOURNAL OF CLINICAL ONCOLOGY (2016)

Add to Collection

Meeting Abstract Oncology

A comparison of outcomes, presentation, and treatment in pediatric (Ped) versus adult patients (Pts) with Ewing sarcoma.

Eric B. Schwartz, Lili Zhao, Brittany Siontis, Laurence H. Baker, Rama Rao, Elizabeth R. Lawlor, Scott Schuetze, Rashmi Chugh

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Meeting Abstract Oncology

Prevalence of HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) among newly diagnosed cancer patients treated in academic and community oncology practices: SWOG S1204.

Scott David Ramsey, Joseph M. Unger, Laurence H. Baker, Richard F. Little, Rohit Loomba, Jessica Hwang, Rashmi Chugh, Monica A. Konerman, Kathryn B. Arnold, Dawn L. Hershman

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Meeting Abstract Oncology

Inferior vena cava leiomyosarcoma: A single-institution experience.

Brittany Siontis, Laurence H. Baker, William Burns, Scott Schuetze, Rashmi Chugh

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Meeting Abstract Oncology

Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa).

Andrew J. Wagner, Richard F. Riedel, Brian Andrew Van Tine, Rashmi Chugh, Kristen N. Ganjoo, Lee D. Cranmer, Seth Pollack, Kamalesh Kumar Sankhala, Erlinda Maria Gordon, Vinod Ravi, Jason L. Hornick, David J. Kwiatkowski, Berta Grigorian, Neil Desai, Mark Andrew Dickson

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Meeting Abstract Oncology

Pilot study investigating an oncofertility program in adults with breast or sarcoma cancers.

Manali A. Bhave, Fang Fang, Kelley M. Kidwell, Gloria Lola Smith, Rashmi Chugh, Monika Leigh Burness

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Review Oncology

Psychosocial, behavioral, and supportive interventions for pediatric, adolescent, and young adult cancer survivors: A systematic review and meta-analysis

Anao Zhang, Bradley Zebrack, Chiu Yi Tan, Emily Walling, Rashmi Chugh

Summary: This study conducted a systematic review and meta-analysis of psychosocial, behavioral, and supportive interventions for pediatric, adolescent, and young adult cancer survivors, showing an overall moderate and statistically significant treatment effect size. However, interventions were not effective for certain outcome domains, and less effective among adolescent and young adult compared to pediatric cancer survivors.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)

Add to Collection

Article Oncology

A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

Sylvia Adams, Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze, Mary D. Chamberlin, Barbara J. Haley, Anna Maria Storniolo, Mridula P. Reddy, Scott A. Anderson, Collin T. Zimmerman, Anne P. O'Dea, Hamid R. Mirshahidi, Jordi Rodon Ahnert, Frank J. Brescia, Olwen Hahn, Jane M. Raymond, David D. Biggs, Roisin M. Connolly, Elad Sharon, Larissa A. Korde, Robert J. Gray, Edward Mayerson, Melissa Plets, Charles D. Blanke, Young Kwang Chae, Razelle Kurzrock

Summary: The combination of ipilimumab and nivolumab has shown promising results in treating advanced metaplastic breast cancer, with an objective response rate of 18%. Some patients have experienced ongoing responses for over 2 years. This combination therapy warrants further investigation and careful consideration of the associated risks.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Oncology

nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors

Andrew J. Wagner, Vinod Ravi, Richard F. Riedel, Kristen Ganjoo, Brian A. Van Tine, Rashmi Chugh, Lee Cranmer, Erlinda M. Gordon, Jason L. Hornick, Heng Du, Berta Grigorian, Anita N. Schmid, Shihe Hou, Katherine Harris, David J. Kwiatkowski, Neil P. Desai, Mark A. Dickson

Summary: The study evaluated the efficacy and safety of nab-sirolimus in patients with malignant PEComa, showing an overall response rate of 39% with rapid and durable responses. Patients with TSC2 mutations were more likely to achieve a positive response. nab-sirolimus was considered an important new treatment option for this disease based on response rate, disease control, and safety profile.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Giant Cell Tumor of Bone: Effect of Longer Dosing Intervals of Denosumab on Tumor Control and Bone-related Complications

Cindy Y. Jiang, Lili Zhao, Scott M. Schuetze, Rashmi Chugh

Summary: In the treatment of giant cell tumors of the bone (GCTB), increasing the interval of denosumab dosing provides similar tumor control compared to standard dosing and reduces the number of bone toxicity events. However, larger studies are needed to determine the optimal dosing interval and its impact on efficacy, toxicity, and healthcare expense.

ONCOLOGIST (2022)

Add to Collection

Article Oncology

Outcome of Patients With Malignant Peripheral Nerve Sheath Tumors Enrolled on Sarcoma Alliance for Research Through Collaboration (SARC) Phase II Trials

Srivandana Akshintala, Nicole C. Mallory, Yao Lu, Karla Ballman, Scott M. Schuetze, Rashmi Chugh, Robert G. Maki, Denise K. Reinke, Brigitte C. Widemann, Ae Rang Kim

Summary: This study analyzes the outcomes of patients with malignant peripheral nerve sheath tumors enrolled on phase II trials conducted by SARC and evaluates the effect of enrollment characteristics on progression-free survival. The results provide a historical baseline for future clinical trials in patients with MPNST.

ONCOLOGIST (2023)

Add to Collection

Meeting Abstract Oncology

Radiation-associated versus sporadic osteosarcoma: A single-institution experience.

Brittany Siontis, Emily Roberts, Lili Zhao, Jonathan B. McHugh, Dawn Owen, Laurence H. Baker, J. Sybil Biermann, Scott Schuetze, Rashmi Chugh

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Meeting Abstract Oncology

Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors.

David Michael Hyman, Ben Tran, Jesus Corral Jaime, Elena Garralda, Jean-Pascal H. Machiels, Jan H. M. Schellens, Phillipe Bedard, Mario Campone, Philippe Cassier, John Sarantopoulos, Ulka N. Vaishampayan, Rashmi Chugh, Amit Mahipal, Albert C. Lockhart, Cristiana Sessa, Thomas Zander, Matthew Ng, Giuseppe Curigliano, Jennifer Bendiske, Jose Manuel Perez-Garcia

JOURNAL OF CLINICAL ONCOLOGY (2016)

Add to Collection

Meeting Abstract Oncology

The who and what of imaging in sarcoma and correlation with survival

Vadim S. Koshkin, Vanessa Bolejack, Lawrence H. Schwartz, Binsheng Zhao, Rashmi Chugh, Richard L. Wahl, Denise K. Reinke, Lee J. Helman, Shreyaskumar Patel, Scott Schuetze, Laurence H. Baker

JOURNAL OF CLINICAL ONCOLOGY (2015)

Add to Collection

Meeting Abstract Oncology

Clinical application of comprehensive next generation sequencing in the management of metastatic cancer in adults

Erin Frances Cobain, Dan R. Robinson, Yi-Mi Wu, Jessica Everett, Erica Rabban, Chandan Kumar, Scott Schuetze, Ajjai Shivaram Alva, Rashmi Chugh, Francis P. Worden, Mark Zalupski, Scott A. Tomlins, Nithya Ramnath, Anne F. Schott, Elena Martinez Stoffel, David C. Smith, Lakshmi Priya Kunju, Daniel F. Hayes, Moshe Talpaz, Arul M. Chinnaiyan

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.